![AbbVie Header](https://www.pharmacompass.com/image/flap/abbvie-header-w29-desktop-header-1gif-4289.gif)
![AbbVie Header](https://www.pharmacompass.com/image/flap/abbvie-header-w29-mobgif-81230.gif)
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.prnewswire.com/news-releases/neurocrine-biosciences-announces-us-fda-accepts-new-drug-applications-and-grants-priority-review-for-crinecerfont-for-pediatric-and-adult-patients-with-cah-302186641.html
https://www.prnewswire.com/news-releases/neurocrine-biosciences-presented-cahtalyst-phase-3-pediatric-and-adult-studies-cahtalog-registry-and-disease--and-glucocorticoid-related-comorbidities-data-in-cah-at-endo-2024-302161888.html
https://endpts.com/neurocrine-ceo-kevin-gorman-to-retire-after-32-year-run-bluebird-picks-up-fifth-cfo-in-three-years/
https://www.fiercepharma.com/pharma/neurocrine-regular-guest-wall-streets-ma-lists-elevates-bd-chief-succeed-founder-ceo
https://www.prnewswire.com/news-releases/neurocrine-biosciences-to-participate-at-investor-conferences-in-june-302157890.html
https://www.prnewswire.com/news-releases/neurocrine-biosciences-announces-ceo-succession-plan-302157140.html
https://www.prnewswire.com/news-releases/neurocrine-biosciences-to-present-new-phase-3-cahtalyst-data-in-adult-and-pediatric-patients-with-cah-and-study-data-for-modified-release-hydrocortisone-in-primary-adrenal-insufficiency-and-cah-at-endo-2024-302155663.html
https://www.reuters.com/business/healthcare-pharmaceuticals/neurocrine-founder-ceo-gorman-retire-october-2024-05-28/
https://www.prnewswire.com/news-releases/neurocrine-biosciences-announces-publication-of-phase-3-kinect-4-post-hoc-analysis-demonstrating-clinically-meaningful-and-sustained-improvement-in-tardive-dyskinesia-with-long-term-use-of-ingrezza-valbenazine-capsules-302151923.html
https://www.prnewswire.com/news-releases/neurocrine-biosciences-presented-baseline-data-from-the-cahtalyst-program-in-cah-and-study-data-for-modified-release-hydrocortisone-in-primary-adrenal-insufficiency-and-cah-at-ece-2024-302144009.html